Shanghai Fosun Pharmaceutical (600196.SH): The application for the registration of metoprolol succinate injection has been approved.

Shanghai Fosun Pharmaceutical (600196.SH) issued an announcement that its controlling subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of metaraminol bitartrate injection (referred to as "the drug"). The approved indications include the restoration of blood pressure in acute hypotensive states, as well as for the auxiliary treatment of cardiac arrest and maintaining blood pressure after cardiac arrest resuscitation. This drug can also be used as an auxiliary treatment for replenishing blood volume during shock caused by inadequate blood volume, in order to raise blood pressure temporarily and maintain cerebral and coronary artery perfusion until the effects of blood volume replenishment treatment take effect.